Sandoz Keeps Tabs On Teva Skinny Label Ruling
As Q3 Sales Reveal ‘Two Sides’ To Sandoz
Executive Summary
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
You may also be interested in...
Pfizer Faces 15-Year Wait On US Adrenalin Generic
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
Trump Most-Favored-Nation Pricing Rule Criticized By The AAM
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
EBITDA Margin Of 33% Not Sustainable, Krka Underlines
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: